Clinical Trial Update: XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric Cancer [Phase 2]

View source ↗

Summary

Clinical trial update on XP (capecitabine/cisplatin) for recurrent gastric cancer in Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Capecitabine (capecitabine)

Snippet

Sponsor: Epidemiological and Clinical Research Information Network | Conditions: Gastric Cancer | Phase 2 | Status: UNKNOWN